These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 12534006)
21. Role for fibrate therapy in diabetes: evidence before FIELD. Vergès B Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243 [TBL] [Abstract][Full Text] [Related]
22. Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study. James P; Tan HH; MacAlpine R; Brennan G; Emslie-Smith A; Morris AD Diabet Med; 2004 Oct; 21(10):1108-12. PubMed ID: 15384958 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic aspects of hyperlipidaemia in diabetes. Durrington PN; Winocour PH Postgrad Med J; 1989; 65 Suppl 1():S33-41. PubMed ID: 2695908 [No Abstract] [Full Text] [Related]
24. Statins and fibrates in the management of diabetic dyslipidemia. Durrington P Diabet Med; 1997 Jul; 14(7):513-6. PubMed ID: 9223386 [No Abstract] [Full Text] [Related]
25. [The FIELD study presented and published. Unconvincing results of fenofibrates in diabetic patients]. Widimský J Vnitr Lek; 2006 Jan; 52(1):80-4. PubMed ID: 16526203 [TBL] [Abstract][Full Text] [Related]
26. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Sacks FM Am J Cardiol; 2008 Dec; 102(12A):34L-40L. PubMed ID: 19084088 [TBL] [Abstract][Full Text] [Related]
27. Fish oil supplements. Med Lett Drugs Ther; 2006 Jul; 48(1239):59-60. PubMed ID: 16841020 [No Abstract] [Full Text] [Related]
28. Is it time to stop treating dyslipidaemia with fibrates? Benatar JR; Stewart RA N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928 [TBL] [Abstract][Full Text] [Related]
29. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). Gudbjörnsdottir S; Eeg-Olofsson K; Cederholm J; Zethelius B; Eliasson B; Nilsson PM; Diabet Med; 2009 Jan; 26(1):53-60. PubMed ID: 19125761 [TBL] [Abstract][Full Text] [Related]
30. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients. Sharma R; Mahajan M; Singh B; Bal BS; Kant R J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006 [TBL] [Abstract][Full Text] [Related]
31. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction. Sacks FM Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082 [No Abstract] [Full Text] [Related]
32. [Statin treatment in type 2 diabetes. Is it a must today?]. Faust M MMW Fortschr Med; 2003 Feb; 145(9):35-6. PubMed ID: 12666527 [No Abstract] [Full Text] [Related]
33. Pharmacologic treatment of type 2 diabetic dyslipidemia. Moon YS; Kashyap ML Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439 [TBL] [Abstract][Full Text] [Related]
34. Preventing diabetic complications: a primary care perspective. Zimmet P Diabetes Res Clin Pract; 2009 May; 84(2):107-16. PubMed ID: 19278746 [TBL] [Abstract][Full Text] [Related]
35. The evidence for lipid lowering: type 2 diabetes and coronary heart disease risk. Townsend D; Davis R Prof Nurse; 2004 Jun; 19(10):38-40. PubMed ID: 15233071 [TBL] [Abstract][Full Text] [Related]
36. Diabetic dyslipidemia and the heart. Vasudevan AR; Garber AJ Heart Fail Clin; 2006 Jan; 2(1):37-52. PubMed ID: 17386875 [No Abstract] [Full Text] [Related]
37. Effect of lipanthyl in hyperlipoproteinaemic diabetic patients. Hajós P; Tornyossi M Ther Hung; 1989; 37(3):138-43. PubMed ID: 2588196 [TBL] [Abstract][Full Text] [Related]
38. Lipid management in patients with diabetes mellitus. Brown AS Am J Cardiol; 2005 Aug; 96(4A):26E-32E. PubMed ID: 16098840 [TBL] [Abstract][Full Text] [Related]
39. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS). Zhao SP; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC; Liu L; Ye HJ; Wu ZH; J Cardiovasc Pharmacol; 2007 Feb; 49(2):81-4. PubMed ID: 17312447 [TBL] [Abstract][Full Text] [Related]
40. Role of fibrates in reducing coronary risk: a UK Consensus. UK HDL-C Consensus Group Curr Med Res Opin; 2004; 20(2):241-7. PubMed ID: 15006019 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]